| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
B Fc Diminishes Prostate Cancer Progression in Bone
1 Department of Pathology
2 Unit for Laboratory Animal Medicine, School of Medicine,
3 Connective Tissue Oncology Program, Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan;
4 Department of Immunology, Tianjin Medical University, Tianjin, China;
5 Department of Cancer Biology, Amgen, Seattle, Washington
Prostate cancer (CaP) develops metastatic bone lesions that consist of a mixture of osteosclerosis and osteolysis. We have previously demonstrated that targeting receptor activator of nuclear factor 
B ligand (RANKL) with osteoprotegerin (OPG) prevents the osteolytic activity of CaP and its ability to establish tumor in bone. However, OPG can block tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis, suggesting that the clinical use of OPG may prevent apoptosis of tumors mediated by TRAIL. Thus, methods to block RANKL activity, other than OPG, may be important. Accordingly, we evaluated the ability of soluble murine RANK-Fc (sRANK-Fc) to prevent progression of established CaP in a severe combined immunodeficient mouse implanted with fetal human bone. We first confirmed that sRANK did not block TRAIL-mediated apoptosis of LuCaP cells in vitro and that it did block LuCaP-conditioned media-induced osteoclastogenesis in vitro. Then, LuCaP 35 CaP cells were injected into the marrow space of the bone implanted in the severe combined immunodeficient mice implanted with fetal human bone and allowed to develop into tumors for 6 weeks. Either vehicle or sRANK-Fc was then administered for 6 weeks. sRANK-Fc diminished tumor-induced osteoblastic lesions as demonstrated by radiograph, bone mineral density measurement, and bone histomorphometry. sRANK-Fc also reduced systemic bone remodeling markers, including serum osteocalcin and bone-specific alkaline phosphatase and urine N-telopeptide of collagen. Finally, sRANK-Fc decreased serum prostate-specific antigen levels and tumor volume in the bone, which indicates decreased tumor burden. In contrast, sRANK-Fc had no effect on s.c. implanted LuCaP cells. We conclude that sRANK-Fc is an effective inhibitor of RANKL that diminishes progression of CaP growth in bone through inhibition of bone remodeling.
This article has been cited by other articles:
|
|
 |
|
  M. K. Crook and T. A. Guise RANKL: Targeting Bone and Cancer to Treat Skeletal Complications of Malignancy IBMS BoneKEy, September 1, 2009; 6(9): 323 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Wilson, K. C. Nannuru, and R. K. Singh Cathepsin G-Mediated Activation of Pro-Matrix Metalloproteinase 9 at the Tumor-Bone Interface Promotes Transforming Growth Factor-{beta} Signaling and Bone Destruction Mol. Cancer Res., August 1, 2009; 7(8): 1224 - 1233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Lamoureux, G. Picarda, J. Rousseau, C. Gourden, S. Battaglia, C. Charrier, B. Pitard, D. Heymann, and F. Redini Therapeutic efficacy of soluble receptor activator of nuclear factor-{kappa}B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma Mol. Cancer Ther., October 1, 2008; 7(10): 3389 - 3398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Miller, M. Roudier, J. Jones, A. Armstrong, J. Canon, and W. C. Dougall RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis Mol. Cancer Ther., July 1, 2008; 7(7): 2160 - 2169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Kearns, S. Khosla, and P. J. Kostenuik Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease Endocr. Rev., April 1, 2008; 29(2): 155 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Fizazi The role of Src in prostate cancer Ann. Onc., November 1, 2007; 18(11): 1765 - 1773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Lu, Z. Cai, G. Xiao, E. T. Keller, A. Mizokami, Z. Yao, G. D. Roodman, and J. Zhang Monocyte Chemotactic Protein-1 Mediates Prostate Cancer-Induced Bone Resorption Cancer Res., April 15, 2007; 67(8): 3646 - 3653. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Vessella and E. Corey Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis. Clin. Cancer Res., October 15, 2006; 12(20): 6285s - 6290s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Cher, D. A. Towler, S. Rafii, D. Rowley, H. J. Donahue, E. Keller, M. Herlyn, E. A. Cho, and L. W.K. Chung Cancer Interaction with the Bone Microenvironment: A Workshop of the National Institutes of Health Tumor Microenvironment Study Section Am. J. Pathol., May 1, 2006; 168(5): 1405 - 1412. [Full Text] [PDF]
|
|
|
|
|
|
H. Ichikawa, A. Murakami, and B. B. Aggarwal 1'-Acetoxychavicol Acetate Inhibits RANKL-Induced Osteoclastic Differentiation of RAW 264.7 Monocytic Cells by Suppressing Nuclear Factor-{kappa}B Activation Mol. Cancer Res., April 1, 2006; 4(4): 275 - 281. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Xu, S. Wang, W. Liu, J. Liu, and X. Feng A Novel Receptor Activator of NF-{kappa}B (RANK) Cytoplasmic Motif Plays an Essential Role in Osteoclastogenesis by Committing Macrophages to the Osteoclast Lineage J. Biol. Chem., February 24, 2006; 281(8): 4678 - 4690. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kitagawa, J. Dai, J. Zhang, J. M. Keller, J. Nor, Z. Yao, and E. T. Keller Vascular Endothelial Growth Factor Contributes to Prostate Cancer-Mediated Osteoblastic Activity Cancer Res., December 1, 2005; 65(23): 10921 - 10929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dai, J. Keller, J. Zhang, Y. Lu, Z. Yao, and E. T. Keller Bone Morphogenetic Protein-6 Promotes Osteoblastic Prostate Cancer Bone Metastases through a Dual Mechanism Cancer Res., September 15, 2005; 65(18): 8274 - 8285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Hall, A. Bafico, J. Dai, S. A. Aaronson, and E. T. Keller Prostate Cancer Cells Promote Osteoblastic Bone Metastases through Wnts Cancer Res., September 1, 2005; 65(17): 7554 - 7560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Weber What's New in Musculoskeletal Oncology J. Bone Joint Surg. Am., June 1, 2005; 87(6): 1400 - 1410. [Full Text] [PDF]
|
|
|
|
|
|
E. Corey, L. G. Brown, J. A. Kiefer, J. E. Quinn, T. E.M. Pitts, J. M. Blair, and R. L. Vessella Osteoprotegerin in Prostate Cancer Bone Metastasis Cancer Res., March 1, 2005; 65(5): 1710 - 1718. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
